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ABSTRACT :  Nephrotoxicity is one of the challenging side effects of acyclovir use in clinical practice. The 
Concomitant use of other nephrotoxic antibiotics, in addition to patient's risk factors, can trigger acyclovir 
induced acute kidney injury (AKI). We described a case of acute meningitis in 68 year old female patient with 
underlying history of ischemic heart disease managed by ticlopidine. The gram stain, culture and PCR of the 
CSF did not show any positive growth of bacterial infection or HSV. However, the negative CSF gram stain and 
culture caused a confusion of the diagnosis of bacterial meningitis with viral meningitis. The patient had AKI 
induced by the treatment with acyclovir for 16 consecutive days and possibly triggered by other AKI risk factors. 
Hemodialysis and hydration did not reverse the kidney function to normal. However, it was reversed to its 
normal status only after the discontinuation of acyclovir. The neutropenic effect of ticlopidine can be a risk to 
the patient that could lead to fatal infection. In this case report we reviewed the literature on the nephrotoxicity 
of acyclovir, the neutropenia of ticlopidine and a proposed role of granulocyte colony stimulating factor (G-
CSF). 
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I. INTRODUCTION 
 The nephrotoxicity of some drugs remains a challenge to the use of these drugs in clinical practices, 
particularly for critically ill patients or for those who are vulnerable to kidney injury. Acyclovir is an anti-viral 
drug which is used in the management of some of the central nervous system (CNS) viral infections [1]. 
Acyclovir nephrotoxicity has been documented [2-4]. Acute kidney injury (AKI) induced by acyclovir could be 
due to intratubular crystal precipitation or direct insult to renal tubular cells [4, 5]. Yet, the co-administration of 
acyclovir with other nephrotoxic drugs, such as aminoglycosides and vancomycin, can accelerate the occurrence 
of AKI [6-9]. This requires careful monitoring while prescribing nephrotoxic anti-microbial therapy. Infectious 
meningitis can be due to bacterial, viral, fungal, mycobacterium and parasites [10]. Except for herpes simplex 
virus infections and meningoencephalitis, viral meningitis can be managed by supportive treatment without 
major consequences [11]. The analysis of  cerebrospinal fluid (CSF) remains the best method to diagnose 
meningitis accurately where the imperative sign of meningitis in CSF analysis is  pleocytosis [12]. However, 
sometimes the CSF analysis does not provide definite indication of the microbial infection causing meningitis. It 
is crucial to start the empirical treatment of bacterial meningitis based on patients’ age and risk factors before 
obtaining the confirmatory CSF lab results to avoid any squalled due to the delay of treatment [12]. In this case 
report, we will describe a case of acyclovir induced AKI which was triggered by the concomitant use of 
amikacin and vancomycin in an acute infectious meningitis patient. The patient was treated with acyclovir for 
16 consecutive days and did not recover from AKI until acyclovir was discontinued.  
II. CASE REPORT 
 A 68 year old Malaysian Chinese woman was referred to the hospital after an initial diagnosis of acute 
bacterial meningitis. This diagnosis was made by another hospital near to her house. The patient had a medical 
history of hypertension, dyslipidemia and hypothyroidism. She was allergic to penicillin. A year ago, she was 
diagnosed with ischemic heart disease (IHD) and had coronary magnetic angiogram and angioplasty. Initially 
she was on daily antiplatelet therapy of 75mg clopidogrel tablets. However, upon her request for cheaper 
antiplatelet, it was changed to 250mg ticlopidine tablets  twice daily since two months ago.  
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 Her other medications included 2mg perindopril tablets to be taken once daily, 10mg amlodipine 
tablets 10mg once daily, 40mg simvastatine tablets once every night, 25mg metoprolol tablets twice daily and 
100µg levothyroxine tablets once daily. She lives with her husband and claimed to be free of smoking and 
alcohol drinking. Three days after returning from a journey to Thailand, she had fever and an episode of 
seizures. She went to a nearby hospital where they suspected that she suffered from meningitis, and had the first 
lumbar puncture (LP) for CSF analysis. The results showed elevated protein and slight pleocytosis; the red 
blood cells (RBCs) were 15 cells/µL, the white blood cells (WBCs) were 5 cells/µL, the protein level was 1.17 
g/L and the glucose was 3.1 mmol/L (reference range (2.2 - 4.2 mmol/L) and blood glucose was 4.2 mmol/L). 
The CSF gram stain, culture, acid fast bacilli and Indian ink wet preparation for cryptococcus was negative, and 
there was no growth. The patient was empirically treated with intravenous (I.V.) ceftriaxone 2g twice daily in 
addition to I.V. phenytoin 100mg every eight hours and intravenous continuous infusion of midazolam.  
 Upon her current admission, the patient was in acute confusion state. Her body temperature was 
37.8°C, the blood pressure was 153/75 mmHg and the pulse rate was 90/minutes. The blood profile showed 
WBCs (10.0 x 10
3
/µL), the relative neutrophils count was slightly low (49.6%), RBCs (4.5 x 10
6
/µL), 
hemoglobin of 13.3 g/dL and platelet count of 169 x 10
3
/µL. The patient renal function on admission was 
normal with creatinine level of 49 µmol/L and calculated creatinine clearance of 99.73 ml/min. The alanine 
aminotransferase (ALT) and alkaline phsosphatase (ALP) were normal but she had a slightly low total amount 
of protein (63 g/L) and albumin (30 g/L). Her thyroid stimulating hormone level was 0.18 mlU/L and thyroxine 
was (22.2 pmol/L). The blood viruses tests showed negative HIV1, non-reactive for both hepatitis B surface 
antigen (HBsAg) and hepatitis C antibody (HCV-3). A computed tomography (CT) scan of the brain indicated 
cerebral atrophy and the absence of intercerebral hemorrahge. The electro encephalogram (EEG) suggested that 
there was severe diffuse encephalopathy. 
 The patient's initial empiric treatment with ceftriaxone was continued for two more days to complete 
four days of treatment which was started by the previous hospital. Then it was changed to I.V. 2g meropenem 
and 500mg acyclovir, both every 8 hours. This therapy continued for 16 days. Although being on antimicrobial 
therapy, the patient's temperature continued to rise up to 39.3°C,  so I.V. 750mg amikacin once daily was added 
on day three (D3). Due to the continuous increase of her temperature and as methicillin resistant staphylococcus 
aureus (MRSA) had been reported before in the same ward, she was suspected of MRSA and she was given I.V. 
vancomycin 750mg once daily on day four (D4). After three days of acyclovir therapy and one day after adding 
amikacin then vancomycin, it was discovered that the serum creatinine level had increased to 255 µmol/L and 
continued to increase to 364µmol/L. In addition, her calculated creatinine clearance had reduced to 13.4ml/min. 
Then, both amikacin and vancomycin were stopped immediately, except for acyclovir. In spite of the 
discontinuation of the two drugs, creatinine level still continue to increase reaching 450 µmol/L and the 
calculated creatinine clearance was 10.7 ml/min. Subsequently, she developed metabolic acidosis and septic 
shock. A diagnosis of sepsis due to drug induced acute kidney injury (AKI) was established and the cause was 
referred to be due to both amikacin and vancomycin. The patient was transferred to the intensive care unit 
(ICU). She was given adequate hydration and had hemodialysis for two times. In spite of the indicated AKI, 
acyclovir treatment was still continued for 16 days. It was discovered that the creatinine level continued to be 
persistently elevated (330 - 225 µmol/L). When acyclovir was stopped, after two days, the creatinine level had 
reduced to 93 µmol/L. It continued to be reduced further to 49 µmol/L after a week of the discontinuation of 
acyclovir. The patient’s body temperature, renal function and physical status were found to be improved. 
 A second LP and CSF analysis was made after ten days of her admission which showed the reduction 
of both protein (0.8 g/L) and WBCs (3 cells/µL). However, the glucose had increased to 5.3 mmol/L. Again, the 
CSF gram stain, culture, acid fast bacilli and Indian ink wet preparation for cryptococcus showed to be negative 
and no growth. A CSF sample was sent for polymerase chain reaction assay (PCR) of herpes simplex virus 
(HSV1) and the result was found to be negative. In addition her antimicrobial therapy, the patient was given I.V. 
250mg leviteracitam twice daily for two weeks and I.V. 100mg phenytoin every eight hours for the seizure. The 
patient's seizures were well controlled and she did not experience any episode of it. The patient continued to 
take her IHD, hypertension, dyslipidemia and hypothyroidism medications until she developed sepsis and they 
were discontinued. Except for ticlopidine which was replaced by clopidogrel, the rest of her medications were 
restarted after her recovery from sepsis.  The patient continued to improve after the completion of 16 days of 
treatment with meropenem and the discontinuation of acyclovir and then ticlopidine. Her liver profile, kidney 
function and blood cell count all become normal on day 26 of her admission. Her full recovery was after thirty 
days of admission and she was discharged. 
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Figure 1: Creatinine levels (Cr) and creatinine clearance (Cr Cl) of the patient during 24 days of her hospital 
stay 
III. DISCUSSION 
 Although acyclovir is a crucial treatment of herpes simplex and varicella zoster viruses [1], its induced 
nephrotoxicity requires judicious decision before using it. Acyclovir induced nephrotoxicity is believed to be 
due to intra-tubular precipitation of crystals [4]. However, recent reports showed that it could be due to the 
direct insult to tubular cells [5]. This requires critical  prescribing, effective hydration and extensive monitoring 
of renal function. There are several risk factors which can aggravate the renal insult of nephrotoxic drugs, such 
as patient's age (> 65 years), female sex, impaired immunity, the duration of using the nephrotoxic drug and 
concurrent use of other nephrotoxic drugs [6, 7, 9, 13]. Acyclovir induced nephrotoxicity can occur within 12-
72 hours after starting the therapy [4, 14]. This nephrotoxicity can lead to AKI if it was not early identified and 
the patient may consequently require hemodialysis [4, 14]. The fast increase in serum creatinine is an important 
indicator of acyclovir nephrotoxicity [15]. To lower the risk of acyclovir nephrotoxicity, hydration with isotonic 
fluids during the administration of the drug is imperative [14]. The cause of AKI in this patient was referred to 
be due to amikacin and vancomycin as the deterioration of renal function occurred after their addition to the 
therapy. 
 
 Vancomycin induced nephrotoxicity usually arise after the prolonged use of it for more than 7 days [7, 
8]. However, in this patient, she was given vancomycin for one dose only and then it was discontinued. The 
incidence of amikacin induced nephrotoxicity usually occur within 4 to 5 days after starting the therapy [8], 
which also was not the case of this patient. However, the co-administration of vancomycin and amikacin can 
accelerate the occurrence of AKI [8, 9]. Despite the discontinuation of both amikacin and vancomycin, adequate 
hydration and the hemodialysis, the renal function of the patient continued to decline with the continuation of 
acyclovir. This could be due to the development of AKI and the patient might had direct tubular insult which 
requires a prompt discontinuation of the drug. It is also worthy to note, that this patient was given ceftriaxone 
for 4 days before replacing it with meropenem. Ceftriaxone can also cause nephrotoxicity [8]. Therefore, due to 
the continuous deterioration of the renal function though the discontinuation of amikacin and vancomycin in this 
patient, we can infer that acyclovir could be the initial cause of nephrotoxicity and the presence of several risk 
factors could had led to the development of AKI. The concurrent use of other nephrotoxic drugs before and after 
starting acyclovir, the patient's age (68 years) and sex (female), all together increased the renal vulnerability to 
develop AKI. As the first CSF analysis PCR assay of HSV1 was negative and the second analysis after one 
week of acyclovir treatment was negative as well, it was optimum to promptly discontinue acyclovir and to 
continue the hydration treatment. 
Acyclovir 
stopped 
Acyclovir 
started 
Hemodialysis 
started 
Amikacin then 
Vancomycin 
added 
Hydration and 2 times 
hemodialysis 
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 Factors such as age, immunity status of the patient, the recent history of neurosurgery and the season of 
the infection can help to determine the type of pathogens that cause meningtis. In adults of more than 50 year 
old, Streptococcus pneumoniae, Neisseria meningitidis, Listeria monocytogenes and aerobic gram negative 
bacilli are the common pathogens [12]. Viral meningitis is usually caused by enterovirus, herpes simplex virus 
(HSV), and varicella-zoster virus [10]. Cryptococcal meningitis and Mycobacterium tuberculosis are common in 
immunodeficient patients such as HIV patients [16, 17]. In bacterial meningitis, CSF analysis usually shows 
white blood cells (WBCs) ≥ 100/µl with predominance of neutrophils, normal glucose and protein ≥ 0.5 g/L [10, 
12]. The positive results of bacterial growth culture and gram stain asserts the pathogenic cause of meningitis. 
However, in many cases the cut off point of diagnosis is not obvious since there may be many factors that may 
interfere. In this report, the patient's CSF analysis did not show positive bacterial gram stain and culture. In a 
study conducted on 297 adults with suspected meningitis, only 1% had been confirmed to have bacterial 
meningitis based on their CSF lab results [18].  The magnetic resonance imaging (MRI) is the preferred imaging 
tool to aid CSF-PCR assay in indicating HSV encephalitis [19]. Some reported cases revealed that MRI is 
significant in the negative results of CSF-PCR assay [20]. Although the CT and EEG showed some 
abnormalities in this case, the MRI was not done for the patient on her initial presentation. This hindered the 
definite diagnosis, thereby leading to the suspicion of herpes simplex encephalitis (HSE). Due to the unclear 
diagnosis of meningitis aetiology in this patient, acyclovir in addition to meropenem continued to be 
administered for 16 consecutive days. 
 
 The use of ticlopidine antiplatelet was reduced in the last decade due to its side effects such as 
neutropenia, thrombotic thrombocytopenic purpurea and liver toxicity [21-25]. In some cases, the occurrence of 
neutropenia can appear after eight weeks from initiation [25, 26]. It was reported that the neutropenic effect of 
ticlopidine had led to fatal outcome in patients with infectious diseases [27, 28]. This patient was having mild 
systemic neutropenia which might be due to the prior use of ticlopidine. The confirmation of her neutropenic 
extent was difficult because there was no record of her neutrophils pre ticlopidine use. Clopidogrel, which is the 
second generation thienopyridine antiplatelet, is safer, less neutropenic and less hepatotoxic [21]. It was 
imperative to replace ticlopidine with clopidogrel. The patient should be warned against the consequences of 
any future replacement of clopidogrel with ticlopidine. 
 
 The Neupogen® (Filgrastim), which is synthesized recombinant protein of the endogenous granulocyte 
stimulating factor (G-CSF), could have role in the management of bacterial meningitis. It is being used to 
overcome neutropenia induced by chemotherapy [29] and other drugs such as ticlopidine [23, 30]. By increasing 
the proliferation of leukocytes, G-CSF will lead to better management of systemic infections and hence will help 
patients to recover from CNS infections [31]. This adjunctive role of G-CSF in treating infections and sepsis 
was investigated in several studies [32-36]. A study in pneumococcal meningitis revealed encouraging results 
[36]. A daily dose of subcutaneous (S.C.) 300µg G-CSF for 6 days, cefotaxime 9-12 g/day for 10 days and 
dexamethasone 16mg/day for 3 days in 22 non-neutropenic patients proved to be  effective and safe [36]. The 
results showed rapid recovery of indices of CSF inflammation, neurological status and an improvement in CSF 
glucose level. Further large scale studies on G-CSF role in infectious meningitis are required to assert its 
adjunctive role. 
IV. CONCLUSION 
 In conclusion, the use of acyclovir, particularly for prolonged therapy, should be considered with care 
of the risk of nephrotoxicity so as to avoid AKI. Concomitance use of nephrotoxic drugs should be avoided 
especially in elderly patients and those with renal impairment. Unless it is being diagnosed of HSE meningitis, 
viral meningitis in adults is self-treated and the prolonged administration of acyclovir is not required. The blood 
count of patients on thienopyridine antiplatelet, particularly ticlopidine, has to be checked periodically to early 
detect any blood discrepancies. The use of adjunctive G-CSF therapy to treat infectious diseases, including 
meningitis, might be substantial but needs further investigations. 
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